22OCT

Nscale raises $3.36bn of notes before New York listing

3 min read

16:30UTC

Third Point led $3.36bn of convertible notes that turn into Nscale shares at its IPO, with $1bn of it due from Nvidia in mid-November.

← Back to Stryker agrees option to buy CMR Surgical Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Nscale's note holders convert at a discount before New York sets its price.

Nscale secured $3.36bn of convertible notes on 25 September, a week after filing for a New York listing, with Third Point leading⁠¹. Convertible notes are loans that turn into shares; these convert at the initial public offering (IPO). A $2.36bn tranche closed at once; a $1bn commitment from Nvidia, expected in mid-November, converts into non-voting shares.

Apollo Global Management, Citadel, Hudson Bay Capital, the Abu Dhabi Investment Council and 8090 Industries also hold notes, and Goldman Sachs was placement agent. No British institution appears among the named holders.

Holders convert at a double-digit discount to the IPO price. The Next Web reported that the discount adjusts up to a $30bn valuation, about double the $14.6bn set in March, above which the conversion price does not move⁠². On those terms, the higher Nscale floats above $30bn, the more the holders gain.

On 28 September a special-purpose vehicle (SPV) named D. Boral Master SPV LLC, Series XIII Nscale filed a Form D with the US Securities and Exchange Commission, the notice for a private sale of securities⁠³. The filing indicates the SPV is selling exposure to Nscale shares to private buyers before any public price exists.

Deep Analysis

In plain English

Nscale is a London company that builds data centres for artificial intelligence, the giant buildings full of computer chips that train and run AI systems. It plans to sell shares on a New York Stock Exchange. Before that, it borrowed $3.36bn through convertible notes. These are loans that turn into shares when the company lists, at a discount to the price new buyers pay. The lenders include the hedge fund Third Point and the chipmaker Nvidia.

Deep Analysis

Root Causes

AI data-centre companies need capital ahead of revenue, because they must buy chips and power before customers pay under long contracts. Convertible notes let Nscale raise that capital now without fixing a share price before the market sets one.

Nvidia's commitment converts into non-voting shares, so the chip supplier gains economic exposure to a large customer without voting control.

What could happen next?

Consequence
The conversion discount means more shares go to note holders at the float, diluting existing shareholders.
Risk
A float priced well below $30bn would still reward note holders while marking down earlier equity investors.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: Spotify sold $1bn of convertible notes to TPG and Dragoneer in 2016, converting at a discount that grew the longer the company waited to list. Spotify went public through a direct listing in 2018, and the note holders converted on favourable terms.

Counter-parallel: WeWork's planned 2019 float collapsed after public investors rejected its private valuation of $47bn, and the company withdrew the listing. A pre-IPO mark set by private money did not hold once the public market priced it.

The immediate effect is $2.36bn of cash on closing and a further $1bn from Nvidia expected in mid-November. The structural effect sits in the conversion terms: holders' shares are priced off the IPO, not off March's $14.6bn mark.

The Form D filed on 28 September by D. Boral Master SPV LLC, Series XIII Nscale points to a secondary market in Nscale exposure before the float. Buyers in such vehicles typically carry the IPO risk without the note holders' discount.

Consensus view: The Next Web reports the notes convert at a double-digit discount to the IPO price, with the discount adjusting up to a $30bn valuation. Third Point, Apollo Global Management and Citadel are buying a guaranteed discount to the float in return for lending before it, and the size of the round shows heavy demand for exposure to AI compute.

Counter-view: Quartz reported that some prospective IPO investors are pushing for a valuation of $16bn to $19bn against a target of roughly $30bn, a claim relayed and not verified. If the float prices near that lower range, the notes still convert at a discount, so note holders are protected in a way that ordinary IPO buyers are not.

Key tension: Whether public investors accept a price close to $30bn for a company whose S-1 showed quarterly revenue just over $100m against a $103.4bn order book.

Sources:The Next Web·US Securities and Exchange Commission

Mentions:Nscale →Third Point →Nvidia →Goldman Sachs →Apollo Global Management →Citadel →Hudson Bay Capital →Abu Dhabi Investment Council →8090 Industries →Securities and Exchange Commission →New York Stock Exchange →Abu Dhabi →New York →London →Spotify →Dragoneer Investment Group →

First Reported In

Update #16 · Stryker agrees option to buy CMR Surgical

The Next Web· 22 Oct 2026

Read original →

Causes and effects

Caused by

Nscale files for New York at $14.6bn

Nscale raised $3.36bn of notes that convert at the IPO it filed for on 18 September.

Occurred 18 Sept 2026

Read story →

This Event

Nscale raises $3.36bn of notes before New York listing

Nscale's largest new backers buy in at a discount before New York sets a public price.

Different Perspectives

Abu Dhabi Investment Council

The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

CDP Venture Capital

CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.

EDBI

Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.

Forbion

Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.

British Business Bank

The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.

Stryker Corporation

Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.